Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A single center and open phase I clinical study on the safety and efficacy of ct103a cell infusion in the treatment of recurrent / refractory plasmacytoma

Next Previous
Trial Profile

A single center and open phase I clinical study on the safety and efficacy of ct103a cell infusion in the treatment of recurrent / refractory plasmacytoma

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 19 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Equecabtagene autoleucel (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Multiple myeloma; Plasma cell leukaemia; Plasmacytoma
  • Focus Adverse reactions
  • Acronyms IIT

Most Recent Events

  • 12 Dec 2023 Results containing updated data from the long-term follow-up of CT103A demonstrating a durable clinical benefit for RRMM patients presented at the 65th American Society of Hematology Annual Meeting and Exposition
  • 14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition
  • 10 Nov 2021 According to an IASO BioMed media release, to date this study has completed 23 cases of reinfusion to date, with at least 2 years of follow-up

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top